Description: Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Home Page: www.ocugen.com
OCGN Technical Analysis
263 Great Valley Parkway
Malvern,
PA
19355
United States
Phone:
484 328 4701
Officers
| Name | Title |
|---|---|
| Dr. Shankar Musunuri M.B.A., MBA, Ph.D. | Co-Founder, Chairman & CEO |
| Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director |
| Dr. Vijay Tammara Ph.D. | Sr. VP of Regulatory & Quality |
| Ms. Jessica Crespo CPA, CPA | Chief Accounting Officer, Sr. VP of Fin. and VP of Corp. Controller & Treasurer |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer |
| Ms. Tiffany Hamilton M.B.A. | Head of Corp. Communications |
| Ms. Zara Gaudioso | AVP, Head of HR & Chief of Staff |
| Mr. Michael Shine | Sr. VP of Commercial |
| Dr. Robert J. Hopkins FACP, M.D., M.P.H. | Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 15.2207 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.6519 |
| Price-to-Sales TTM: | 25069.316 |
| IPO Date: | 2014-12-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 56 |